In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

In arm 1 of the trial, the dose-escalation portion, patients will receive mRNA-4106 at a test dose as monotherapy. In arm 2, ...

Prof Martin Dreyling discusses the shifting treatment landscape for patients with difficult-to-treat mantle cell lymphoma.

In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the use of chimeric antigen receptor ...